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Summary 
BACKGROUND 
Many people with human immunodeficiency virus (HIV) are undiagnosed. Early diagnosis 
saves lives and reduces onward transmission. We tested the hypothesis that an education 
programme promoting rapid HIV testing in general practice would lead to increased and 
earlier HIV diagnosis. 
METHODS 
In a cluster randomised controlled trial in east London, 40 of 45 (89%) general practices were 
randomised and either trained to offer opt-out rapid HIV testing to newly registering adults, 
or continued usual care. The primary outcome was CD4 count at diagnosis. 
FINDINGS  
During the study 44,971 adults registered with 20 intervention practices, and 38,464 with 20 
controls. Intervention practices newly diagnosed 32 people with HIV compared with 14 in 
control; rate of HIV diagnosis was fourfold higher in intervention than control practices: 0·30 
per 10,000 patients per year (95% CI, 0·11 to 0·85) versus 0·07 (95% CI, 0·02 to 0·20); 
adjusted ratio of geometric means: 4·51 (95% CI, 1·27 to 16·05; P=0·021). Mean CD4 count 
at diagnosis was 356 cells/μL (SD 254) intervention versus 270 (SD 257) control; adjusted 
difference in square root CD4 count: 3·1 (95% confidence interval [CI], -1·2 to 7·4; P=0·16); 
in a pre-planned sensitivity analysis excluding patients diagnosed via antenatal care, this 
difference was 6·4 (95% CI, 1·2 to 11·6; P=0·017). All people diagnosed via rapid testing 
were successfully transferred into specialist care. No adverse events have occurred during the 
trial.  
INTERPRETATION 
Promoting opt-out rapid testing in general practice led to increased and earlier detection of 
HIV.  
FUNDING 
Department of Health, NHS City and Hackney; (ClinicalTrials.gov: ISRCTN63473710). 
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Introduction 
Timely diagnosis of HIV remains a major challenge. Undetected HIV and late diagnosis are 
associated with ill health, increased risk of death and onward viral transmission, constituting 
a significant burden to public health budgets worldwide.1-3 Of 107,800 people living with 
HIV (PLHIV) in the UK, almost one quarter are undiagnosed,4 42% are diagnosed late (after 
they should have begun antiretroviral treatment, CD4<350), and 24% diagnosed very late 
(CD4<200).4 These figures are mirrored in the World Health Organisation (WHO) European 
Region and the USA, where an estimated one half of 2·2 million, and one sixth of 1·1 million 
PLHIV respectively, are undiagnosed.1,5,6 
Expanding HIV testing is key to improving HIV outcomes. In 2008, the British HIV 
Association (BHIVA) recommended universal HIV testing in primary care settings in high 
prevalence areas (2 per 1000 population), in addition to the routine screening programmes in 
antenatal settings and STI clinics.7 This approach was endorsed by the National Institute for 
Health and Care Excellence (NICE).8,9 Pilot projects have shown the acceptability and 
feasibility of HIV testing in primary care.10-12  However, wide-spread adoption of HIV testing 
in these non-traditional settings is lacking; in particular, there is no evidence on outcomes 
from robust screening trials. The US Preventative Services Task Force recently noted: ‘no 
randomised trial or observational study compared clinical outcomes between adults and 
adolescents screened and not screened for HIV infection,13 a conclusion also reached by the 
UK National Institute for Health and Care Excellence.8,9 To our knowledge, there is no 
randomised trial evidence that HIV screening leads to increased and earlier diagnosis. This 
represents a key evidence gap in current guidance.14,15  
Primary care is ideally placed to offer HIV testing.7 General practices provide health checks 
for newly registering patients and are a referral point to specialist care. HIV testing in general 
practice is feasible and acceptable.10,11,16 and may be preferable for people who would not 
normally attend traditional HIV testing settings such as sexual health clinics.11  
We report on a pragmatic cluster randomised controlled trial (RCT) to test the hypothesis that 
a multifaceted educational outreach programme promoting rapid HIV testing in general 
practice leads to increased and early diagnosis of HIV. We used a cluster randomised design 
because the intervention was directed at practices, rather than individual patients. 
PANEL – Research in context – about here 
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Methods 
The study was set in Hackney , a multi-ethnic, socioeconomically deprived inner London 
borough, which has the ninth highest rate of diagnosed HIV infection (8 per 1000 adult 
population) in the UK. 4 There were no exclusion criteria for clusters. At entry, practices 
offered no systematic screening for HIV but did carry out opportunistic serology testing 
where clinically indicated. Visiting midwives offered HIV screening for women receiving 
antenatal care. Consent from participating practices was sought before randomisation. The 
study ran from April 2010 to August 2012. An independent data monitoring committee 
(DMC) was established.  
Participants 
Patients aged 16 years (the age of consent to medical procedures in the UK) and older, who 
newly registered with study practices and were able to undertake a pre−test discussion in 
English, or with a suitable translator, were included. Patient information sheets, available in 
English and eight locally spoken languages, were displayed at reception desks. The ethics 
committee approved a process of valid implied consent for patient participation.16  
 
Randomization of general practices and masking 
Practices were randomised between April 2010 and August 2011 by an independent clinical 
trials unit statistician using a minimisation program (Minim, v1·3),17 maintaining allocation 
concealment. Minimisation criteria were: practice list size (<5,000 registered patients; 5,000-
7000; 7,000); practice deprivation (Index of Multiple Deprivation score:<47; 47);18 and 
male HIV testing rate (male adults tested between April and October 2009/male adults 
registered x1000: <7; 7). The nature of the intervention meant that neither investigators nor 
clinical teams were masked to allocation. 
Procedures 
The intervention was multifaceted and comprised:  
 a practice-based outreach educational program, with follow up training for a 
nominated practice HIV lead nurse or health care assistant (HCA); 
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 integration of rapid HIV testing into the registration health check and management of 
reactive tests; 
 provision to the practices of free rapid HIV tests and payment of £10 ($16·14) per test 
completed; 
 Quality assurance testing programme. 
The educational programme was based on proven theory-based clinician behaviour change 
strategies from the literature together with our experience of delivering similar effective 
interventions.19-21 Initial training sessions were held at individual practices, lasted 90 minutes, 
targeted the whole practice team, and included didactic and interactive elements. Session 
leaders (WL, HM) were trained to ensure intervention fidelity (Supplement A). Rapid HIV 
test operators completed competency-based training. An HIV lead was nominated in each 
practice to co-ordinate rapid testing and quality assurance (Supplement B). 
Registration health checks are performed by a nurse or HCA, who follow prompts on a 
template in the patient’s electronic health record. We inserted additional prompts to offer 
rapid HIV testing, linked to bespoke Read codes (http://www.hscic.gov.uk/) to record test 
outcomes: non-reactive, reactive, indeterminate, invalid, and test declined. Read coding 
enabled remote data collection of testing activity (Supplement C). The INSTI HIV1/HIV2 
Rapid Antibody Test (bioLytical Laboratories, Canada) finger prick system was used for 
rapid testing. 
 
The intervention was adaptable to each individual practice: e.g. staff could additionally offer 
rapid HIV testing in a range of clinical settings (e.g. sexual health checks) and were 
encouraged to continue opportunistic HIV testing by serology. 
The core components of the testing process included:  
 an offer of a rapid HIV test as part of the routine new registration health check to 
eligible patients including a pre-test discussion for them to make an informed decision 
regarding the HIV testing; 
 a rapid HIV test followed by a post-test discussion for patients with a non-reactive 
test result;  
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 an immediate notification of the rapid test operator to the general practitioner (GP) of 
any patient with a reactive/indeterminate/twice invalid test result with confirmatory 
serology sampling, and follow up by a GP (Supplement D).  
Any venous blood sample detected as reactive for HIV 1 or 2 on an Abbott Architect ci8200 
analyser at Homerton Hospital was sent on for confirmatory testing at NHS Bart Health Trust 
using the Bayer ADVIA Centaur anti-HIV 1 & 2 test, the BioMerieux VIDAS HIV DUO 
Quick, and the Alere ImmunoComb II HIV 1 & 2 BioSpot.  
Patients confirmed HIV1/HIV2 antibody positive (Supplement E) were referred to Homerton 
Hospital for specialist care. Practices implemented rapid testing immediately after the 
educational session. Ongoing support from the education team was available to practice staff 
for queries related to rapid testing via telephone or email. Control practices were informed by 
email about current national guidance on HIV testing. All study practices continued to 
provide standard care of HIV testing and were supported by a community HIV liaison nurse.  
At Homerton Hospital, all patients testing HIV positive at participating practices were 
allocated a unique study number. Newly diagnosed patients were distinguished from known 
HIV positive patients already in care or defaulted from specialist care using the Genitourinary 
Medicine Clinical Activity Dataset.22 The Homerton clinical team (JA, SM) extracted clinical 
record data onto anonymised confidential clinical case report forms. Accuracy of data 
extraction for all patients was verified by an independent clinician (AM), blinded to study 
allocation, before being passed to the study statistician. For more details on patient 
ascertainment, see Supplement G. 
Rapid HIV antibody test result codes were specifically generated for the trial as follows: 
EMISNQRE117 (reactive), EMISNQNO26 (non-reactive), EMISNQIN61 (indeterminate), 
and EMISNQIN62 (invalid). The following additional READ codes were used: HIV 
[serology] screening test (4JR7) and rapid HIV test declined (8I3P). Rapid HIV testing data 
and serology testing data were remotely extracted from general practice computer systems 
(EMIS, Egton Medical Information Systems Limited; and Vision, In Practice Systems 
Limited; [both UK]) by the Clinical Effectiveness Group at Queen Mary, University of 
London (KP, MS, AC, and JD).  
 
Outcomes 
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Early and increased diagnosis of HIV are key clinical and public health outcomes.4, 7-9 The 
primary outcome measure was the mean CD4 count at diagnosis of newly diagnosed patients. 
Women newly diagnosed with HIV by the UK Antenatal HIV Screening Programme were 
included. For exclusion criteria for the primary outcome and definition of a newly diagnosed 
patient, see Supplement F. Secondary outcome measures were number of new HIV diagnoses 
(expressed as rate: patients diagnosed/year/10,000 practice list size), and percentages of 
patients with CD4<350 and CD4<200. 
The original primary outcome for the study was the number of new HIV diagnoses. However, 
our initial assumptions were based on limited data and the number of new diagnoses early in 
the study was lower than expected. Thus, early in the trial, and with the approval of the data 
monitoring committee, we recalculated statistical power with CD4 count as the primary 
outcome, retaining numbers of new diagnoses as the main secondary outcome. For clarity we 
report both outcomes.  
 
Statistical analysis 
Allowing for clustering, and assuming 20 practices in each arm and analysis of CD4 on the 
square root scale with a SD of 6 and ICC of 0·05, we expected to identify 72 new HIV 
diagnoses, with 80% power and 5% significance. This would be sufficient to detect an 
increase in the mean CD4 count from 300 to 470 cells/μL, corresponding to a reduction in the 
proportion of late presenters from 30% to 10%. Allowance was made for practices to identify 
variable numbers of patients or none at all.23  
Intervention effect on CD4 count and rate of diagnosis was estimated using a linear 
regression model adjusted for clustering of practices in Stata (v12) using the cluster option 
(except for rate of diagnosis where practice summary data was used) and adjusted for 
minimisation factors. CD4 count was transformed using a square root transformation and rate 
of diagnosis was log transformed after adding 0·01 to zero counts. Using the intervention 
effect from the primary analysis and the normal distribution, we estimated the relative 
reduction in percentage of patients diagnosed with both CD4<350 and CD4<200 cells/μL 
using a novel method developed by Peacock et al, 2012.24  
Although we originally planned a secondary, as treated secondary analysis based on 
excluding all practices who had done less than 50 tests, this was not feasible as there were 
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only four practices in this category and no patients from these practices had been . This was 
recorded in the statistics analysis plan. 
The UK Antenatal HIV Screening Programme offers all women in antenatal care an HIV test. 
We carried out a pre-planned sensitivity analysis excluding women diagnosed via this 
programme. 
Some patients testing positive had previously been diagnosed but had defaulted from 
specialist care: ‘re-diagnosis’ in general practice therefore led to re-entry to specialist care. A 
further sensitivity analysis therefore included those testing positive who had defaulted from 
care. 
 
Role of the funding source 
NHS City & Hackney and the Department of Health co-funded the study.  
JF, a clinician employed by NHS City and Hackney, was involved in co-designing the study, 
data interpretation, and writing of the report, but had no role in data collection or analysis. 
The Department of Health had no role in any aspect of the study. The corresponding author 
had full access to all the data in the study and had final responsibility for the decision to 
submit for publicationResults 
General practices and populations 
Forty of 45 (89%) general practices agreed to take part; and five declined (Figure 1). The five 
practices that declined participation had similar characteristics to those that joined the study. 
Twenty practices were randomised to intervention and 20 to the control group. Three 
intervention practices withdrew during the study (one stopped offering registration health 
checks; one for workload reasons; and one closed), but all provided complete study data and 
were included in the intervention arm in the analysis (intention to treat). Practice and 
population characteristics and numbers of newly registering patients were well balanced after 
randomisation (Tables 1a and 1b). 
Intervention practices offered 11,187 rapid tests, of which 4,978 (44.5%) were accepted 
(Table 2). Of these, 4,964 were not reactive and 14 were reactive, including 11 that were 
confirmed HIV positive (true reactive) and three confirmed HIV negative (false reactive). 
INSERT FIGURE 1 (Flow chart) here 
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INSERT TABLE 1a and 1b (Practice and patient characteristics) here 
INSERT TABLE 2 (HIV tests and diagnoses) here 
INSERT TABLE 3 (CD4 counts) here  
Overall, intervention practices identified 43 HIV positive patients, of whom 11 had 
previously been diagnosed, giving a total of 32 new HIV diagnoses, 11 of which were 
diagnosed by rapid testing. Control practices identified 21 HIV positive patients, of which 
seven had previously been diagnosed, giving a total of 14 new HIV diagnoses (Figure 1). 
The UK Antenatal Screening Programme led to three new HIV diagnoses in intervention 
practices, and four in controls.  
Of the 32 new diagnoses in the intervention group, 19 (59%) were men, 20 (63%) were of 
black African origin, and six (16%) were men who have sex with men (MSM). Of the 14 
patients diagnosed in control practices, eight (57%) were men, and 10 (71%) were of black 
African origin; no MSM were recorded in the control group, although there were no data on 
sexual orientation for three men. No adverse event occurred during the study. 
Primary outcome: CD4 count at diagnosis 
CD4 count data were available in 30 of the 32 newly diagnosed patients from intervention 
practices, and in all 14 patients from controls. The mean CD4 count in intervention practices 
was higher compared to control: 356/μL (SD 254), and 270/μL (SD 257) respectively, but not 
significantly so; (adjusted difference in square root transformed CD4: 3·1; 95% confidence 
interval [CI], -1·2 to 7·4; P=0·16, Table 3).  Two pre-planned sensitivity analyses showed 
that the effect of the intervention on CD4 count was significantly greater when patients 
diagnosed via the UK antenatal HIV screening program were excluded (6·4; 95% CI, 1·2 to 
11·6; P0·017, Table 3), and when patients who had been previously diagnosed with HIV but 
defaulted from care were included in the analysis (4·1; 95% CI, 0·0 to 8·1; P=0·049, Table 
3). 
Secondary outcomes 
Rate of new HIV diagnoses 
Rate of HIV diagnosis was fourfold higher in intervention than control practices: with 0·30 
(95% CI, 0·11 to 0·85) per 10,000 patients per year in the intervention, and 0·07 (95% CI, 
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0·02 to 0·20) in the control arm; (adjusted ratio of geometric means: 4·51; 95% CI, 1·27 to 
16·05; P=0·021, Table 2). In a sensitivity analysis, the effect of intervention on rates of 
diagnoses was similar in all population subgroups (Table 2). 
Proportions of diagnoses with CD4 counts <350, and <200 cells/μL 
Using a method developed by Peacock et al (2012),24  we estimated that  of patients in the 
control practices had a CD4 count less than 350 cells/μL, compared with of intervention 
patients; (risk ratio 0·75, 0·53 to 1·07). Corresponding figures for CD4 less than 200 cells/μL 
were 46% versus 28%; (risk ratio 0·60, 0·32 to 1·13). 
Discussion 
We demonstrate that an educational outreach programme promoting opt-out rapid HIV 
testing of people newly registering in general practice leads to increased and earlier diagnosis 
of HIV. These are key goals of HIV-focussed clinical and public health programmes. Effects 
were more strongly significant in sensitivity analyses excluding women diagnosed through 
the UK’s existing antenatal HIV screening programme. Practices used both rapid (N=11 
newly diagnosed patients) and opportunistic serology testing (N=21 patients) to make new 
diagnoses. A high proportion (62%) of newly diagnosed patients were of Black African 
origin, reflecting successful integration of testing into a multi-ethnic community, recognised 
as a hard to reach population.25 To our knowledge this is the first randomised trial to 
demonstrate improvements in clinical outcomes from HIV screening.  
Strengths of our study included a pragmatic ‘real world’ design that included almost all 
practices (89%) in the borough, improving generalisability of our findings. Randomisation 
was robust, maintaining allocation concealment. Analysis was by cluster at the level of 
general practices. Remote searching of practice computer systems ensured consistent data 
capture of testing activity and outcomes across practices. Access to test results from the 
regional laboratory ensured complete capture of all positive tests, minimising detection bias. 
The Public Health England national surveillance system allowed accurate distinction between 
patients newly diagnosed in primary care from those who had previously tested positive. 
Validation of data extraction by an independent clinician, blinded to allocation, of all newly 
diagnosed patients ensured accuracy and completeness of primary and secondary outcomes. 
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Our multi-faceted intervention was based on a previously successful screening intervention 
for tuberculosis in general practice,19 which used a variety of effective behaviour change 
techniques. The effectiveness of outreach visits, and clinician education combining mixed 
didactic and interactive elements, is well established.26 Computer prompts to testing and 
incentive fees may also have enhanced behaviour change.27 A quality assurance scheme, 
which included competency-based training for rapid HIV testing, regular electronic 
monitoring of point-of-care results and bi-monthly assessment of staff using external control 
serum samples, enhanced patient safety by reducing the chances of false positive rapid test 
results. All patients diagnosed via rapid testing were successfully transferred to secondary 
care indicating that the links we established between general practice and specialist services 
were safe and effective. Some patients who had defaulted specialist care re-entered specialist 
services following a ‘re-diagnosis’ by their GP, suggesting that primary care can play an 
important role in maintaining the patient care continuum. 
A weakness was that three intervention practices discontinued testing. These discontinuations 
reflect the pragmatic real world study design. We were, nonetheless, able to include complete 
data from all practices in the analysis. Registration health checks are optional, thus only those 
that attend (about 50% of all registering patients) can be offered a test. Increasing attendance 
at checks would increase the impact of our intervention. Whilst it was impossible to blind 
clinical and research teams to allocation, validation of data extraction by a blinded 
independent clinician helped ensure validity of study data.  
Observational studies suggest that targeted community-based approaches to HIV testing 
achieved high uptake, and a higher proportion of cases with CD4 count at diagnosis >350.28 
In community centres in the USA, nurse-initiated routine universal non-targeted rapid HIV 
testing achieved similar uptake and yields of new diagnoses to those seen in the current 
study.29 Nurse-initiated rapid testing with streamlined counselling in primary care is feasible 
compared to traditional approaches.29,30 These observations lend credibility to our findings.  
Our findings provide firm evidence that HIV screening in primary care leads to increased and 
earlier HIV diagnosis. This finding addresses a key gap in the evidence base for HIV testing, 
lending randomised evidence in support of guideline recommendations.  
Our results justify renewed efforts to implement community screening for HIV. This study 
builds on our previous work showing opt-out screening for tuberculosis using a multi-faceted 
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educational intervention and valid implied consent is effective in primary care.19 Screening 
for multiple infectious agents in at-risk populations seems justifiable.  
Our findings provide robust high quality evidence to support HIV screening programmes in 
primary care to reduce undiagnosed and late diagnosed infection in high prevalence settings. 
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PANEL - Research in context 
Evidence before this study: 
We searched PubMed for randomised controlled trials, from year 2000 to 2009, testing the 
effects of screening for HIV in primary care on rate of HIV diagnosis and stage of 
diagnosis, according to the following PICO: 
Populations:  Adults 
Interventions: HIV screening and HIV testing interventions 
Comparator:  Randomized controlled trials with usual care as a comparator 
Outcomes:  Rate of HIV diagnosis; CD4 count; HIV stage of diagnosis 
We found no studies that met these criteria. 
A similar search was carried out in 2011 by the US Preventative Services Task Force as 
part of their evidence review to update the 2005 U.S. Preventive Services Task Force 
recommendations on HIV screening. They noted: ‘no randomised trial or observational 
study compared clinical outcomes between adults and adolescents screened and not 
screened for HIV infection’ 
Added value: 
These findings provide, to our knowledge, the first robust randomised evidence that a 
screening programme leads to increased and early HIV diagnosis 
Implications:  
Public Health leads should consider implementing primary care based screening for HIV 
in high prevalence areas 
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